Efficacy and Safety of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Recurrent Uterine Leiomyosarcoma: Results of a Phase 2 Study.
Beatrice J Sun, Maggie Y Zhou, Marti Lohman et al.
✦ AI-curated · Sources linked
In 30 seconds
This Phase II open-label study evaluated the safety and efficacy of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) using gemcitabine for patients with recurrent uterine leiomyosarcoma (uLMS). Among 17 patients, the median progression-free survival was 11 months, significantly longer than the historical control of 3 months (p < 0.001).
Key findings
- Median progression-free survival was 11 months, compared to 3 months in historical controls (p < 0.001).
- All patients achieved complete cytoreduction (CCR 0).
- No Clavien-Dindo grade 3 complications were reported.
- Two patients experienced grade 4 toxicities, including hypokalemia and neutropenia.
Why it matters
The findings suggest that CRS combined with HIPEC may enhance outcomes for patients with recurrent uLMS, a condition known for poor prognosis. Understanding the potential benefits and safety profile can inform treatment decisions in this challenging patient population.
What to keep in mind
The study was closed early due to slow patient accrual, which may limit the generalizability of the results.